Cyclerion Therapeutics, Inc.
Small-molecule therapeutic (CYC-126) for treatment-resistant depression
New patent ·
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2018
- Latest Form D
- $5M, May 2023
- Total capital
- $222M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $222M
- 4 Form D · last May 2023
- 41 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2021
- Rank in peer group#65 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$5M
- Private capital raisedForm D · SEC · 3rd filing$18M
- Private capital raisedForm D · SEC · 2nd filing$24.3M
- Private capital raisedForm D · SEC · 1st filing$175M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#65 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Amy E. SchulmanDirectorNamed in SEC Form D filings
- Andreas M. BuschExecutive OfficerNamed in SEC Form D filings
- Anjeza M. GjinoExecutive OfficerNamed in SEC Form D filings
- Cheryl M. GaultExecutive OfficerNamed in SEC Form D filings
- Errol M. De SouzaDirectorNamed in SEC Form D filings
- George G. ConradesDirectorNamed in SEC Form D filings
Show all 16 people
- Kevin M. ChurchwellDirectorNamed in SEC Form D filings
- Mark G. CurrieExecutive OfficerNamed in SEC Form D filings
- Marsha E. FanucciDirectorNamed in SEC Form D filings
- Michael G. MendelsohnDirectorNamed in SEC Form D filings
- Ole E. IsacsonDirectorNamed in SEC Form D filings
- Peter M. HechtExecutive Officer, DirectorNamed in SEC Form D filings
- Stephanie M. LovellDirectorNamed in SEC Form D filings
- Steven M. HymanDirectorNamed in SEC Form D filings
- Terrance M. McGuireDirectorNamed in SEC Form D filings
- William G. HuyettExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- New patentTREATMENT OF DIABETIC NEPHROPATHY WITH AN sGC STIMULATORUSPTOUS 12,758,550
- PendingNovel Processes for Preparation of Soluble Guanylate Cyclase StimulatorsUSPTOApplication 19046836
- PendingNovel Process For Preparation Of Soluble Guanylate Cyclase StimulatorsUSPTOApplication 19187279
Show all 40 patent records
- TREATMENT OF DIABETIC NEPHROPATHY WITH AN sGC STIMULATOROct 13, 2026 · US 12,758,550Granted
- Novel Processes for Preparation of Soluble Guanylate Cyclase StimulatorsJun 18, 2026 · Application 19046836Pending
- Novel Process For Preparation Of Soluble Guanylate Cyclase StimulatorsApr 16, 2026 · Application 19187279Pending
- Processes And Intermediates For The Preparation Of Soluble Guanylate Cyclase StimulatorsNov 27, 2025 · Application 19176742Pending
- Solid Forms Of An Sgc StimulatorSep 11, 2025 · Application 19016255Pending
- Solid Dispersions Comprising A Sgc StimulatorAug 14, 2025 · Application 19054072Pending
- sGC STIMULATORSJul 31, 2025 · Application 18947124Pending
- PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORSJul 31, 2025 · Application 18947131Pending
- Solid Forms Of An Sgc StimulatorApr 24, 2025 · Application 18818111Pending
- Processes And Intermediates For The Preparation Of Soluble Guanylate Cyclase StimulatorsApr 15, 2025 · US 12,275,724Granted
- Novel Processes For Preparation Of Soluble Guanylate Cyclase StimulatorsMar 11, 2025 · US 12,247,025Granted
- Solid Dispersions Comprising A Sgc StimulatorJan 16, 2025 · Application 18665775Pending
- Treatment Of Hfpef In Post-menopausal Women With An Sgc StimulatorNov 7, 2024 · Application 18292747Pending
- Phosphorus Prodrugs Of Pyrazolo-substituted Pyrimidine Sgc StimulatorsOct 31, 2024 · Application 18411480Pending
- Solid Dispersions Comprising A Sgc StimulatorSep 5, 2024 · Application 18400392Pending
- Solid Forms Of An Sgc StimulatorJul 25, 2024 · Application 18500565Pending
- Novel Processes And Intermediates For The Preparation Of Soluble Guanylate Cyclase StimulatorsJul 9, 2024 · US 12,030,874Granted
- TREATMENT OF DIABETIC NEPHROPATHY WITH AN sGC STIMULATORMay 23, 2024 · Application 17773274Pending
- Phosphorus Prodrugs Of Pyrazolo-substituted Pyrimidine Sgc StimulatorsApr 25, 2024 · Application 18241630Pending
- Solid Forms Of An Sgc StimulatorFeb 22, 2024 · Application 18204997Pending
- Novel Process For Preparation Of Soluble Guanylate Cyclase StimulatorsFeb 22, 2024 · Application 18237435Pending
- Novel Processes For Preparation Of Soluble Guanylate Cyclase StimulatorsDec 5, 2023 · US 11,834,444Granted
- Process For Preparation Of Soluble Guanylate Cyclase StimulatorsOct 3, 2023 · US 11,773,089Granted
- sGC STIMULATORSAug 22, 2023 · US 11,731,977Granted
- Novel Processes And Intermediates For The Preparation Of Soluble Guanylate Cyclase StimulatorsJul 25, 2023 · US 11,708,361Granted
- TREATMENT OF CNS DISEASES WITH sGC STIMULATORSJul 4, 2023 · US 11,690,828Granted
- sGC STIMULATORSApr 6, 2023 · Application 17556213Pending
- Solid Forms Of An Sgc StimulatorFeb 7, 2023 · US 11,572,358Granted
- CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORSOct 11, 2022 · US 11,466,015Granted
- Process For Preparing Soluble Guanylate Cyclase StimulatorsOct 11, 2022 · US 11,466,014Granted
- Treatment Of Metabolic Syndrome With An Sgc StimulatorJul 19, 2022 · US 11,389,449Granted
- USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)Jun 14, 2022 · US 11,357,777Granted
- Processes For Preparation Of Soluble Guanylate Cyclase StimulatorsMay 3, 2022 · US 11,319,308Granted
- Novel Processes And Intermediates For The Preparation Of Soluble Guanylate Cyclase StimulatorsMar 15, 2022 · US 11,274,096Granted
- sGC STIMULATORSDec 28, 2021 · US 11,207,323Granted
- Sgc StimulatorsNov 23, 2021 · US 11,180,493Granted
- Pyrazole Derivatives As Sgc StimulatorsJul 22, 2021 · Application 17143933Pending
- sGC STIMULATORSJul 15, 2021 · Application 17122542Pending
- sGC STIMULATORSMar 25, 2021 · Application 17112351Pending
- PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORSFeb 23, 2021 · US 10,927,136Granted
Related companies, and why
- Apnimed, Inc.Similar federal contract value in Biotech · null in contracts
- Seaport TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Rivus PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Endeavor BioMedicinesSimilar federal contract value in Biotech · null in contracts
- AbsciSimilar federal contract value in Biotech · null in contracts
- Generation BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .